Hypera S.A. (HYPMY)
| Market Cap | 2.87B -2.6% |
| Revenue (ttm) | 1.74B +29.5% |
| Net Income | 350.44M +121.0% |
| EPS | 0.49 +107.5% |
| Shares Out | n/a |
| PE Ratio | 8.42 |
| Forward PE | 7.75 |
| Dividend | 0.26 (6.39%) |
| Ex-Dividend Date | Oct 5, 2026 |
| Volume | 9,897 |
| Open | 4.000 |
| Previous Close | 4.020 |
| Day's Range | 4.000 - 4.150 |
| 52-Week Range | 3.390 - 5.770 |
| Beta | 0.13 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 27, 2026 |
About Hypera
Hypera S.A. operates as a pharmaceutical company in Brazil. The company provides sweeteners products under the Adocyl, finn, and Zero-cal brands; analgesics and anti-inflammatories products under the Doril, Atroveran, Calminex, Alivium, Buscopan, Buscofem, geloll, Torsilax, Neosaldina, and naprohax brands; cold and flu remedies and decongestants products under BENEGRIO, Rinosoro, Blu, Neosoro, Coristina, APRACUR, and Fluviral brands. It offers antihistamines products under Alektos, Histamin, Polaramine, PredSim, and Desrinite brands; antiseptic... [Read more]
Financial Performance
In 2025, Hypera's revenue was 7.70 billion, an increase of 3.45% compared to the previous year's 7.44 billion. Earnings were 1.20 billion, a decrease of -10.86%.
Financial numbers in BRL Financial StatementsNews
Hypera Earnings Call Transcript: Q3 2026
Q3 revenue rose 9.4% YoY and sell-out outpaced the market, with Semavy driving momentum. EBITDA conversion reached 97.5%, while net debt fell to BRL 5.6bn; management prioritized deleveraging and expects CapEx to decline as projects conclude.
Hypera Earnings release: Q3 2026
Hypera released its Q3 2026 earnings on October 28, 2026, summarizing the period's financial results.
Hypera Quarterly report: Q3 2026
Hypera has published its Q3 2026 quarterly earnings report on October 28, 2026.
Hypera Slides: Q3 2026
Hypera has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 28, 2026.
Hypera upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs upgraded Hypera (HYPMY) to Buy from Neutral with a price target of R$26, up from R$25. After a quarter of solid free cash flow generation in Q2 on…
Hypera Earnings Call Transcript: Q2 2026
Q2 2026 saw robust revenue, EBITDA, and net income growth, with strong cash flow and reduced net debt. New launches in GLP-1 and women's health are set to drive future growth, while working capital and margin improvements are expected to continue.
Hypera Quarterly report: Q2 2026
Hypera has published its Q2 2026 quarterly earnings report on August 7, 2026.
Hypera Earnings release: Q2 2026
Hypera released its Q2 2026 earnings on August 7, 2026, summarizing the period's financial results.
Hypera Slides: Q2 2026
Hypera has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 7, 2026.
Hypera initiated with a Buy at Jefferies
Jefferies initiated coverage of Hypera (HYPMY) with a Buy rating and R$28.70 price target The firm names Hypera its preferred name in Latin America pharma, saying the company company offers…
Hypera upgraded to Buy from Neutral at Citi
Citi analyst Leandro Bastos upgraded Hypera (HYPMY) to Buy from Neutral with a price target of R$28, up from R$26. The firm cites the company’s stricter working capital conditions and…
Hypera Earnings Call Transcript: Q1 2026
Q1 2026 saw 87% revenue growth and 9.5% sell-out increase, driven by new launches and logistics gains. Net debt fell nearly 20% after a BRL 1.5 billion capital increase, with strong cash flow and margin performance. Outlook remains positive, with further launches and inventory optimization expected.
Hypera Earnings release: Q1 2026
Hypera released its Q1 2026 earnings on April 28, 2026, summarizing the period's financial results.
Hypera Slides: Q1 2026
Hypera has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 28, 2026.
Hypera Quarterly report: Q1 2026
Hypera has published its Q1 2026 quarterly earnings report on April 28, 2026.
Hypera Slides: Corporate presentation
Hypera has posted slides in relation to its latest quarterly earnings report, which was published on April 2, 2026.
Hypera Earnings Call Transcript: Q4 2025
Sellout grew 6.8% in 2025, with net revenue up 3.4% and record operating cash flow after working capital optimization. Entering 2026, the company expects further efficiency gains, strong cash flow, and growth from new launches, especially semaglutide, pending regulatory approval.
Hypera Earnings release: Q4 2025
Hypera released its Q4 2025 earnings on March 13, 2026, summarizing the period's financial results.
Hypera Slides: Q4 2025
Hypera has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 13, 2026.
Hypera Annual report: Q4 2025
Hypera has published its Q4 2025 annual report on March 13, 2026.
Hypera Earnings Call Transcript: Q3 2025
Net revenue rose 16% year-over-year to BRL 2.2 billion, with EBITDA margin at 34% and record operational cash flow. Retail outperformed the market, while institutional sales declined; strong pipeline and new launches are expected to drive future growth.
Hypera Earnings release: Q3 2025
Hypera released its Q3 2025 earnings on October 28, 2025, summarizing the period's financial results.
Hypera Slides: Q3 2025
Hypera has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 28, 2025.
Hypera Quarterly report: Q3 2025
Hypera has published its Q3 2025 quarterly earnings report on October 28, 2025.
Hypera Earnings Call Transcript: Q2 2025
Sell-out grew 5.5% in Q2 2025, outpacing the market, with strong acceleration in May–July. Working capital optimization improved efficiency and margins, while net revenue reached R$2.2 billion and EBITDA margin was 33.7%. Focus remains on deleveraging and sustainable growth.